Praxis Precision Medicines, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PRAX Nasdaq 2834 praxismedicines.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 3rd, 2026 2:01 pm
Praxis (PRAX) Q2 2026 Earnings Call Transcript - Aug 13th, 2026 10:29 am
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - Aug 11th, 2026 8:01 am
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Aug 8th, 2026 4:12 pm
Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary - Aug 7th, 2026 6:30 am
Praxis Precision Medicines Q2 Earnings Call Highlights - Aug 7th, 2026 2:04 am
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... - Aug 6th, 2026 5:15 pm
Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath. - Aug 6th, 2026 2:12 pm
These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months - Aug 6th, 2026 11:49 am
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Aug 6th, 2026 6:00 am
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - Jul 30th, 2026 2:01 pm
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs - Jul 15th, 2026 8:01 am
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - Jul 7th, 2026 6:00 am
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies - Jun 29th, 2026 2:30 pm
Praxis Precision Medicines Gains After FDA Grants Breakthrough Therapy Designation - Jun 22nd, 2026 6:47 am
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants - Jun 22nd, 2026 6:00 am
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up - Jun 14th, 2026 9:11 pm